These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22114865)

  • 1. An observational study of the discrediting of COX-2 NSAIDs in Australia: Vioxx or class effect?
    Parkinson L; Doljagore X; Gibson R; Doran E; Notley L; Stewart Williams J; Kowal P; Byles JE
    BMC Public Health; 2011 Nov; 11():892. PubMed ID: 22114865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What happened to the prescribing of other COX-2 inhibitors, paracetamol and non-steroidal anti-inflammatory drugs when rofecoxib was withdrawn in Australia?
    Barozzi N; Tett SE
    Pharmacoepidemiol Drug Saf; 2007 Nov; 16(11):1184-91. PubMed ID: 17636557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: a retrospective study of physician-patient pairs in Taiwan.
    Hsiao FY; Tsai YW; Huang WF
    Clin Ther; 2009 Nov; 31(11):2618-27. PubMed ID: 20110006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What therapies have replaced rofecoxib in Ireland?
    Teeling M; O'Connor H; Feely J; Bennett K
    Br J Clin Pharmacol; 2007 Oct; 64(4):536-41. PubMed ID: 17555468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of the withdrawal of rofecoxib on prescribing patterns of COX-2 inhibitors in Scotland.
    Williams D; Singh M; Hind C
    Br J Clin Pharmacol; 2006 Sep; 62(3):366-8. PubMed ID: 16934053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prescription of nonselective NSAIDs, coxibs and gastroprotective agents in the era of rofecoxib withdrawal - a 617,400-patient study.
    Valkhoff VE; van Soest EM; Masclee GM; de Bie S; Mazzaglia G; Molokhia M; Kuipers EJ; Sturkenboom MC
    Aliment Pharmacol Ther; 2012 Oct; 36(8):790-9. PubMed ID: 22928490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of reported gastrointestinal and thromboembolic events between rofecoxib and celecoxib using observational data.
    Kasliwal R; Layton D; Harris S; Wilton L; Shakir SA
    Drug Saf; 2005; 28(9):803-16. PubMed ID: 16119973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perceived barriers to paracetamol (acetaminophen) prescribing, especially following rofecoxib withdrawal from the market.
    Barozzi N; Tett SE
    Clin Rheumatol; 2009 May; 28(5):509-19. PubMed ID: 19132456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NSAID use in individuals at risk of renal adverse events: an observational study to investigate trends in Australian veterans.
    Roughead EE; Ramsay E; Pratt N; Gilbert AL
    Drug Saf; 2008; 31(11):997-1003. PubMed ID: 18840019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data.
    Layton D; Heeley E; Hughes K; Shakir SA
    Rheumatology (Oxford); 2003 May; 42(5):622-31. PubMed ID: 12709537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy switching and associated costs in elderly patients receiving COX-2 selective inhibitors or non-selective non-steroidal anti-inflammatory drugs in Quebec, Canada.
    Rahme E; Toubouti Y; Hunsche E
    Rheumatology (Oxford); 2006 Jul; 45(7):903-10. PubMed ID: 16461440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
    Miao XP; Li JS; Ouyang Q; Hu RW; Zhang Y; Li HY
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD007744. PubMed ID: 25340915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data.
    Layton D; Heeley E; Hughes K; Shakir SA
    Rheumatology (Oxford); 2003 Nov; 42(11):1342-53. PubMed ID: 12832706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crystal structure of rofecoxib bound to human cyclooxygenase-2.
    Orlando BJ; Malkowski MG
    Acta Crystallogr F Struct Biol Commun; 2016 Oct; 72(Pt 10):772-776. PubMed ID: 27710942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Assessment of the number of cardio- and cerebrovascular events due to rofecoxib (Vioxx) in Germany between 2001 and 2004].
    Sawicki PT; Bender R; Selke GW; Klauber J; Gutschmidt S
    Med Klin (Munich); 2006 Mar; 101(3):191-7. PubMed ID: 16648975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and evaluation of a possible signal of exacerbation of colitis during rofecoxib treatment, using Prescription-Event Monitoring data.
    Layton D; Heeley E; Shakir SA
    J Clin Pharm Ther; 2004 Apr; 29(2):171-81. PubMed ID: 15068407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization.
    Sun SX; Lee KY; Bertram CT; Goldstein JL
    Curr Med Res Opin; 2007 Aug; 23(8):1859-66. PubMed ID: 17605893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NSAID switching and short-term gastrointestinal outcome rates after the withdrawal of rofecoxib.
    Schneeweiss S; Glynn RJ; Avorn J; Mamdani M; Mogun H; Solomon DH
    Pharmacoepidemiol Drug Saf; 2009 Dec; 18(12):1134-42. PubMed ID: 19844943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in the characteristics of patients prescribed selective cyclooxygenase 2 inhibitors after the 2004 withdrawal of rofecoxib.
    Setakis E; Leufkens HG; van Staa TP
    Arthritis Rheum; 2008 Aug; 59(8):1105-11. PubMed ID: 18668614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.
    Watson DJ; Harper SE; Zhao PL; Quan H; Bolognese JA; Simon TJ
    Arch Intern Med; 2000 Oct; 160(19):2998-3003. PubMed ID: 11041909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.